@article { author = {Elyasi, Forouzan and Rezaei, Maedeh}, title = {Topiramate-Induced Oral Lichenoid Lesions: A Case Report}, journal = {Journal of Iranian Medical Council}, volume = {5}, number = {3}, pages = {527-531}, year = {2022}, publisher = {Iran Medical Council}, issn = {2645-338X}, eissn = {2645-3398}, doi = {http://dx.doi.org/10.18502/jimc.v5i3.10951}, abstract = {AbstractTopiramate is being widely used to prevent migraine headaches and treat epilepsy and mental disorders; however, Oral Lichenoid Lesion (OLL) is one of its rare side effects. The present report has been provided based on a patient case study who had developed OLLs following treatment with topiramate. The patient was a 50-year-old woman referred to a psychiatric clinic with complaints of severe headaches, anxiety, insomnia, and symptoms of Obsessive-Compulsive Disorder (OCD). For this purpose, fluoxetine, topiramate, and nortriptyline were prescribed. Two months after increasing the topiramate dosage to 400 mg per day, she developed OLLs. The Topiramate dose was reduced within two weeks and finally discontinued. The lesions were removed four weeks after the cessation. The patient had no lesions for 6 months. With restarting the drug, the lesion reappeared and finally, ceasing topiramate usage. To conclude, the mentioned lesions are one of the rare complications of this anticonvulsant drug. }, keywords = {case report,Diagnosis,Lichenoid lesion,oral,Side Effects,Topiramate }, url = {http://www.jimc.ir/article_159869.html}, eprint = {http://www.jimc.ir/article_159869_003200d29ac7f7a3c4fc681a6774220e.pdf} }